Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441344 for active systemic lupus erythematosus
2021-001567-25Phase 2Active
- Sponsor
- Sanofi
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing SAR441344 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Percentage of participants achieving SRI-4 response at Week 24. Started Jul 2021; status: active.
02
Drugs
frexalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2021-001567-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001567-25.